Two more studies come to light on aspirin and cancer. As two new American scientific studies report, regular aspirin can reduce the risk of both ovarian and liver cancer.
The first study, led by Dr. Molly Barnard of the Harvard School of Public Health, published in the American Journal of Oncology JAMA Oncology, was based on data analysis for 205,500 women, of whom 1,054 were diagnosed with ovarian cancer.
Women taking regular aspirin at a dosage of up to 100 milligrams had a 23% lower risk of ovarian cancer than those who did not use aspirin. However, there was not the same benefit for those who received regular dosing aspirin (325 milligrams).
Aspirin is believed to reduce the risk of cancer because it reduces inflammation in the body. On the other hand, it was found that long-term intake of other non-steroidal anti-inflammatory drugs is probably associated with an increased risk of this cancer in women.
The second epidemiological study, led by Dr. Tracey Simon of the Gastroenterology Department of the Massachusetts General Hospital, published in the same oncology journal, shows that regular use of aspirin at regular dosing (at least two tablets of 325 milligrams a week) 49% the risk for hepatocellular carcinoma, a common type of liver cancer.
The study, involving more than 133,300 people, indicates that the risk of this cancer decreases as the dosage and duration of aspirin is increased (eg a 59% risk reduction for aspirin for at least one five-year period). but it involves the risk of bleeding in the gastrointestinal tract.
The main cause of hepatocellular carcinoma is cirrhosis of the liver, which can be caused by hepatitis B or C, alcohol abuse, etc. Aspirin also acts as a protective agent due to its anti-inflammatory preventative action.
It may increase the life expectancy of certain cancer patients
It is noted that regular aspirin may increase the life expectancy of some cancer patients, according to a British scientific study. Many patients are more likely to survive if they take a small dose of aspirin every day.
Researchers at the Welsh University of Cardiff, headed by Professor Peter Elwood, who published the publication in PLoS One, evaluated (meta-analysis) 71 investigations involving a total of approximately 520,000 cancer patients, of whom 120,000 were aspirin; 400,000 no.
The study concluded that the survival rate of cancer patients was 20% to 30% greater if they were taking aspirin regularly. Also, the spread of cancer to other parts of the body (metastases) was lower in those who took aspirin daily.
“The use of low-dose aspirin as a prevention of heart disease, stroke and cancer is all but given, but evidence now suggests that aspirin can also play a valuable role as an additional treatment for cancer,” Elwood said.
Most studies involved bowel, breast and prostate cancers. However, some of the studies did not find any benefit of aspirin, so further studies on the aspirin-cancer relationship are needed. On the other hand, according to the researchers, the risk of severe bleeding due to aspirin was found to be low,